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Background: AChlamydia trachomatis infection (chlamydia) can result
in tubal factor infertility in women. To assess if this association results in
fewer pregnant women, we aimed to assess pregnancy incidences and time
to pregnancy among women with a previous chlamydia infection compared
with women without one and who were participating in the Netherlands
Chlamydia Cohort Study (NECCST).
Methods: The NECCST is a cohort of women of reproductive age tested
for chlamydia in a chlamydia screening trial between 2008 and 2011 and
reinvited for NECCST in 2015 to 2016. Chlamydia status (positive/negative)
was defined using chlamydia screening trial–nucleic acid amplification test
results, chlamydia immunoglobulin G presence in serum, or self-reported
chlamydia infections. Data on pregnancies were collected via question-
naires in 2015–2016 and 2017–2018. Overall pregnancies (i.e., planned
and unplanned) and time to pregnancy (among women with a pregnancy
intention) were compared between chlamydia-positive and chlamydia-negative
women using Cox regressions.
Results:Of 5704 women enrolled, 1717 (30.1%; 95% confidence interval
[CI], 28.9–31.3) women was chlamydia positive. Overall pregnancy propor-
tions were similar in chlamydia-positive and chlamydia-negative women
(49.0% [95%CI, 46.5–51.4] versus 50.5% [95%CI, 48.9–52.0]). Pregnan-
cies per 1000 person-years were 53.2 (95% CI, 51.5–55.0) for chlamydia
negatives and 83.0 (95% CI, 78.5–87.9) for chlamydia positives. Among
women with a pregnancy intention, 12% of chlamydia-positive women
had a time to pregnancy of >12 months compared with 8% of chlamydia
negatives (P < 0.01).
Conclusions: Overall pregnancy rates were not lower in chlamydia-positive
women compared with chlamydia-negative women, but among women with
a pregnancy intention, time to pregnancy was longer and pregnancy rates
were lower in chlamydia-positive women.
Trial registration number: Dutch Trial Register NTR-5597.
S tudies over the last 20 years show a stable 3% Chlamydiatrachomatis (chlamydia) infection prevalence among Dutch
women in the ages between 16 and 34 years.1–3 Chlamydia can
cause pelvic inflammatory disease, which can then result in tubal
scarring due to an intense and chronic inflammatory response.4
Tubal scarring may lead to tubal factor infertility (TFI).5 In the
Netherlands, TFI was diagnosed in approximately 11% of infertile
couples between 2002 and 2004.6 It is estimated that approximately
1% of women will develop TFI after chlamydia infection.7,8 In the
case of high chlamydia prevalence in a population, this will result
in considerable numbers of infertilewomen.Womenwith chlamydia-
related TFI may need medical assistance, for example, in vitro fer-
tilization (IVF) to become pregnant.9 However, the mean chance
of a live birth after IVF—with large variability because of determi-
nants such as age and cause of infertility—has been estimated at
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only approximately 42% after 3 complete IVF cycles.10 Hence, we
hypothesized that pregnancy rates are lower, or time to pregnancy is
longer among women with a previous chlamydia infection versus
women without a previous chlamydia infection.
So far, only a few studies have assessed the association be-
tween chlamydia infections and subsequent pregnancies or births.
A large retrospective study (>20,000 women included) compared
birth rates between women who tested chlamydia positive either
by serology or by DNA test compared with women with negative
test results only.11 No differences in birth rates between chlamydia-
positive and chlamydia-negativewomen were found. Similar results
were found in a historical follow-up study from Denmark in which
again >20,000 women were included; birth rates (alive or stillborn)
were similar between chlamydia-seropositive and chlamydia-seronegative
women.12 In both studies, exposure time was calculated from a
first chlamydia test onward. Factors such as sexual behavior, pre-
vious contraceptive use, intention to conceive, and time to preg-
nancy in months were unknown in these studies and noted as
limitations. These limitations need to be addressed to determine
true differences in pregnancies between chlamydia-positive and
chlamydia-negative women.
One main aim of chlamydia control is to prevent complica-
tions like infertility through early testing and treating infections. It
is therefore important to focus not only on chlamydial-induced infer-
tility but also on fertility after infection.We investigated differences in
pregnancy incidences and time to pregnancy between womenwith
andwithout a previous chlamydia infection, where timewas defined
as the months women attempted to conceive and where factors such
as sexual (risk) behavior, intention to conceive, and contraceptive
use were included.
MATERIALS AND METHODS
Study Design and Participants
In the Netherlands Chlamydia Cohort Study (NECCST),
Dutch women of reproductive age are followed up until 2022.
The design of NECCST has been described previously.13 Briefly,
in 2008 to 2011, women between the ages of 16 to 29 years partic-
ipated in the population-based chlamydia screening implementation
study (CSI).2 During CSI, women received annual invitations for
chlamydia nucleic acid amplification tests (NAATs). Women who
participated at least once and gave consent to be approached for fur-
ther research were invited to participate in NECCST in 2015 to
2016 (Fig. 1). Participants gave online informed consent to comply
with study procedures for the collection of repeat questionnaires and
biological samples.
Procedures
The first NECCST data collection round included an elec-
tronic questionnaire followed by a test kit for self-collection of
blood via a finger-prick for chlamydia immunoglobulin G (IgG)
analysis. The capillary blood samples, collected in tubes (BD
Microtainer SST, Franklin Lakes, NJ), were returned to the labora-
tory via mail. Time between blood collection and storage was a
median of 4 days (interquartile range [IQR], 3–5 days), which
was previously validated.14 Serum samples were stored at −20°C
until thawed for enzyme-linked immunosorbent assay (Medac
CT IgG ELISA plus, Wedel, Germany) with a sensitivity of 71%
and specificity of 97%.14,15 Presence of chlamydia IgG served as
a marker for previous infection. In 2017 to 2018, participants were
invited to complete the second questionnaire. Both questionnaires
retrospectively enquired about chlamydia infections, pregnancy
intention, pregnancies, and time to pregnancy in months. In addi-
tion, demographic factors were collected such as migration back-
ground and education level. Migration background was classified
as “Western” if both parents had aWestern country of birth, that is, a
country from Europe (excluding Turkey), North America, Oceania,
Indonesia, and Japan; “non-Western” if at least 1 parent had a
non-Western country of birth; and “unknown” if one parent was
Western while the country of birth of the other parent was un-
known or when the country of birth of both parents was unknown.
Education level was defined as low/medium (no education, primary
education only, lower general secondary education, and vocational
education) and high (higher professional education and university
education) at last completed questionnaire. Furthermore, sexual be-
havior, other sexually transmitted infections, contraceptive use, and
health characteristics were addressed. For all events (i.e., chlamydia
infections, gonorrhea infections, and pregnancies), timing in cal-
endar year was requested in order to reconstruct a timeline. Sub-
sequently, CSI data about chlamydia NAAT results, self-reported
Figure 1. Study inclusion flowchart.8
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chlamydia infections, and age of sexual debut were merged with
NECCST data.
Definitions
Chlamydia Status
Women were defined as chlamydia positive if they were ei-
ther chlamydia-NAAT positive in CSI, chlamydia positive by IgG
antibody presence, or self-reported an infection during CSI or
NECCST; women were considered positive from the year of first
infection onward. If women were tested negative by NAAT, were
tested negative for chlamydia antibodies, and did not report a pre-
vious infection, they were defined as chlamydia negative.
Overall Pregnancies
Pregnancy was defined as a self-reported pregnancy, which
also included miscarriages and induced abortions. Overall preg-
nancies included planned aswell as unplanned pregnancies, and ir-
respective of fertility treatments.
Women With a Pregnancy Intention
This includes allwomenwho had at least one planned preg-
nancy (irrespective of fertility treatments) or who had ever tried to
conceive or were still trying.
Time Period of the Cohort
Women were first invited for the CSI study between 2008
and 2011. Women were invited for NECCST in 2015 or 2016 and
reinvited in 2017 or 2018. The cohort period was shortest from
2011 to 2015 and longest from 2008 to 2018. The last received
questionnaire was dated August 21, 2018.
Exposure time in Cox regression was defined in 2 ways.
-First, to assess the chance of getting pregnant for chlamydia-positive
women compared with chlamydia-negative women, exposure
time was defined as the years since sexual debut until last com-
pleted questionnaire. This starting point was chosen because from
sexual debut on, women were “at risk” for chlamydia infection
and (unplanned) pregnancies.
-Second, to determine the chance of getting pregnant over time for
chlamydia-positive women compared with chlamydia-negative
women, time to pregnancy was defined as the number of months
women attempted to become pregnant until first planned preg-
nancy, until she stopped attempting to get pregnant, or until the
last completed questionnaire.
Statistical Analyses
Population characteristics, pregnancy proportions, and time
to pregnancy were compared between chlamydia-positive women
and chlamydia-negativewomen using Student t test,Mann-Whitney
U tests, and χ2 tests. In addition, pregnancy incidence rates (calcu-
lated as the number of pregnancies divided by total person-years at
risk) were given.
Overall Pregnancies
The association between chlamydia and getting pregnant
was assessed through a Kaplan-Meier curve and Cox regression
among all participants. To include multiple pregnancies per partic-
ipant, we used recurrent event analyses based on the method of
Prentice et al.,16 which is known as the conditional risk set model.
In this model, the assumption is that a subject is not at risk for a
second event until the first event has occurred, and so on. Risks
were expressed in (adjusted) hazard ratios, or (a)HRs. Chlamydia
status was included as a time-varying variable. Multiple imputa-
tions were done to estimate the time of first chlamydia infection
if this was unknown, that is, in women with a positive chlamydia
IgG result only (a positive IgG result can be a result of an infection
from years earlier). With STATA's multiple imputation command
using truncated regression analyses with 10 simulation data sets,17,18
time of first chlamydia infection after sexual debut was estimated
based on available data fromwomen with a known year of first infec-
tion. This was done for 222 women (4% of all participants and 13%
among chlamydia-positive women). The proportional-hazard (PH)
assumption was checked using log-log plots and testing Schoenfeld
residuals. Effect modification, to identify whether the effect of
chlamydia infection was different in groups with different charac-
teristics, was assessed for the following variables: age, sex of the
partner, andmigration background. In the case of significant effect
modification, analyses were stratified. The following variables were
considered potential confounders and included in the model if
there was a ≥10% change in the regression coefficient: age
(time-varying), migration background, and educational level. In
addition, smoking behavior and body mass index category at
the start of NECCST, gonorrhea infection, number of lifetime
sex partners, age of sexual debut, and condom use with casual
partner were considered potential confounders.
Women With a Pregnancy Intention
Timing in months until the first planned pregnancy and
chlamydia status was also assessed by Kaplan-Meier curves and
Cox regression. All women with a pregnancy intention were in-
cluded in this analysis. The PH assumption and effect modifica-
tion were assessed as described previously. Chlamydia status was
negative in the case of no positive test outcome or in the case that
a first planned pregnancy occurred before the first chlamydia diag-
nosis. Chlamydia status was defined as positive when the first in-
fection occurred before the first planned pregnancy. The following
potential confounders at time of trying to get pregnant, in addition
to confounders described previously, were evaluated: age, body
mass index, last contraceptive, and smoking behavior. Contracep-
tive use was categorized as follows: no contraceptive use, hormonal
contraceptives, Mirena, copper intrauterine device, or condoms.
TABLE 1. Sensitivity Analyses
Sensitivity Analyses
1 Analyses were repeated without multiple imputations, i.e., women
without a known year of first chlamydia infection were excluded
2 Analyses were repeated selecting CSI-NAAT–positive women
versus chlamydia-negative women because of high sensitivity
and specificity and no recall bias using CSI-NAAT results.
In addition, to understand the impact of measurement bias,
an analysis was performed where chlamydia was classified
as NAAT negative, NAAT positive, serology positive,
or self-reported positive.
3 The analysis was restricted to women who participated in both
the first and second questionnaire rounds of NECCST to test
for selection bias response.
4 Analyses were repeated where we excluded women with a
first chlamydia infection that occurred in the same year as a
first pregnancy because of the possibility that the infection
occurred after the pregnancy rather than before.
5 Analyses were repeated where we excluded women who had
their first infection diagnosed after a planned pregnancy
6 Analyses were repeated in which chlamydia status was
categorized as chlamydia negative, one infection, or
multiple chlamydia infections.
7 Last, analyses were repeated in which chlamydia status was
categorized as chlamydia negative, chlamydia positive, or
chlamydia seropositive only.
Pregnancies and C. trachomatis Infection
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Sensitivity Analyses
Various sensitivity analyses were performed as described in
Table 1.
Medical Ethical Approval
This study was approved by theMedical Ethical Committee
VUMedical Center, Amsterdam, theNetherlands (NL51553.094.14/
2015.903[A2019.336]). All participants provided informed consent.
RESULTS
In total, 5704 women were enrolled in NECCST and com-
pleted the initial questionnaire. In 2017/2018, 5676 (99.5%; n = 28
study withdrawals) women were invited to complete the second
NECCST questionnaire, of whom 3622 (63.5%) did (Fig. 1). To-
tal exposure time from sexual debut until last questionnaire was
93,854 person-years.
TABLE 2. Study Population Characteristics by Chlamydia Status at Timing of Last Data Collection Moment
Overall, n (%)
Chlamydia
Negative, n (%)
Chlamydia
Positive, n (%) P
Overall 5704 (100.0) 3987 (69.9) 1717 (30.1)
Chlamydia status
Negative 3987 (69.9) 3987 (100.0) 0 (0.0) <0.01
Positive by category
Self-reported 900 (15.8) 0 (0.0) 900 (52.4)
CSI-NAAT 4 (0.1) 0 (0.0) 4 (0.2)
Chlamydia IgG 208 (3.7) 0 (0.0) 208 (12.1)
Self-reported + CSI-NAAT 244 (4.3) 0 (0.0) 244 (14.2)
Self-reported + chlamydia IgG 263 (4.6) 0 (0.0) 263 (15.3)
CSI-NAAT + chlamydia IgG 1 (0.0) 0 (0.0) 1 (0.1)
All positive 97 (1.7) 0 (0.0) 97 (5.7)
Age, mean (SD), y 32.4 (3.9) 32.5 (3.9) 32.1 (3.9) <0.01
Migration background
Western 4565 (80.0) 3354 (84.1) 1211 (70.5) <0.01
Non-Western 869 (15.2) 458 (11.5) 411 (23.9)
Unknown 270 (4.7) 175 (4.4) 95 (5.5)
Educational level*,†
Low/middle 1163 (20.4) 648 (16.3) 515 (30.0) <0.01
High 4539 (79.6) 3338 (83.7) 1201 (70.0)
Age at sexual debut, mean (SD), y
<16 1558 (27.3) 956 (24.0) 602 (35.1) <0.01
16–17 2178 (38.2) 1507 (37.8) 674 (30.8)
>17 1968 (34.5) 1524 (38.2) 444 (25.9)
Lifetime sex partners
<6 1306 (22.9) 1077 (27.0) 229 (13.3) <0.01
6–12 2174 (38.1) 1598 (40.1) 576 (33.6)
>12 2224 (39.0) 1312 (32.9) 912 (53.1)
Condom use with casual partners‡
Never/not often 340 (6.0) 242 (6.1) 98 (5.7) <0.01
Sometimes 1807 (31.7) 1081 (27.2) 726 (42.3)
Always/mostly 2610 (45.9) 1876 (47.2) 734 (42.8)
No casual partners 936 (16.4) 779 (19.6) 157 (9.2)
Gonorrhea positivity, n (%) 120 (2.1) 36 (0.9) 84 (4.9) <0.01
Use of IUD
Never 3507 (61.5) 2471 (62.0) 1036 (60.3) 0.24
At least once 2197 (38.5) 1516 (38.0) 681 (39.7)
Smoking
Never 2260 (39.6) 1712 (42.9) 548 (31.9) <0.01
Sometimes/in the past 2919 (51.2) 1981 (49.7) 938 (54.6)
Daily 525 (9.2) 294 (7.4) 231 (13.5)
BMI§
<20 730 (12.8) 536 (13.5) 194 (11.3) <0.01
20–<25 3448 (60.6) 2437 (61.2) 1011 (59.0)
25–<30 1052 (18.5) 713 (17.9) 339 (19.8)
≥30 464 (8.2) 294 (7.4) 170 (9.9)
Chlamydia-positivewas defined as a positive NAAT test outcome in the CSI study (CSI-NAAT), and/or the presence of chlamydia IgG or a self-reported chla-
mydia infection.
*Educational level: low/medium level of education: no education, primary education only, lower general secondary education and vocational education;
high level of education: all other education levels.
†At start of NECCST and based on 5702 observations, 2 missing.
‡Based on 5693 observations, 11 missing and based on first questionnaire data.
§based on 5694 observations, 10 missing.
BMI indicates body mass index; CSI, chlamydia screening implementation. IgG, Immunoglobulin G; IUD, intrauterine device; NAAT, nucleic acid ampli-
fication test.
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TABLE 3. Pregnancies in Chlamydia-Negative and Chlamydia-Positive Women
All Women,
Chlamydia-Negative
Women
Chlamydia-Positive
Women
n % (95% CI) n % (95% CI) n % (95% CI)
Never pregnant nor tried 2558 44.9 (44–46) 1821 44.7 (43.1–46.2) 737 45.3 (42.9–47.8)
Tried or trying and failed to become pregnant 291 5.1 (4.5–5.7) 198 4.9 (4.2–5.6) 93 5.7 (4.6–7.0)
Ever pregnant* 2855 50.1 (48.7–51.4) 2058 50.5 (48.9–52.0) 797 49.0 (46.5–51.4)
Planned (at least once) 2051 71.8 (70.1–73.5) 1558 75.7 (73.8–77.5) 493 61.9 (58.4–65.2)
Pregnancies per 1000 person-years 58.4 (56.7–60.0) 53.2 (51.5–55.0) 83.0 (78.5–87.9)
*Thirty-five women who had a previous unplanned pregnancy were also trying to get pregnant without success yet. In this table, they are included in the
ever pregnant category.
CI indicates confidence interval.
Figure 2. Kaplan-Meier plots of years since sexual debut until first pregnancy (A) and time to a planned pregnancy in months among women
with a pregnancy intention (B) by chlamydia status. Chlamydia positive was defined as a positive NAAT test outcome in the CSI study
(CSI-NAAT), and/or the presence of chlamydia IgG and/or a self-reported chlamydia infection.
Pregnancies and C. trachomatis Infection
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Study Population
Characteristics of the study population by chlamydia status
at last data collection round (either the first or second NECCST
questionnaire round) are presented in Table 2. Mean (SD) age was
32.0 (3.9) years. Eighty percent of women had a high educational
level and a Western migration background. Thirty percent of women
were chlamydia positive. Comparedwith chlamydia-negativewomen,
chlamydia-positive women were younger at sexual debut, had more
lifetime sex partners, had a history of gonorrhea more often, and
were more often smokers.
Overall Pregnancies
In total, 3146 (55.2%) women (ever) tried to become preg-
nant or were pregnant at least once (Table 3). Mean age at first
pregnancy was 29.4 years (95% CI, 29.2–29.6 years). There was
no significant difference in percentage of women who had ever
tried/were trying to become pregnant, had been pregnant, or had
never tried to become pregnant between chlamydia-negative
women and chlamydia-positive women (P = 0.316).
Pregnancy incidences are described in Table 3. The
Kaplan-Meier curve is presented in Figure 2A. Timewas censored
at 23 years after sexual debut because of sample size reduction.
The Schoenfeld residuals test (P = 0.001) indicated that the chance
ratio of getting pregnant was not proportional over time. There-
fore, to calculate HRs, the exposure time was stratified in 4 inter-
vals based on graphs and testing the PH assumption. In the first 2
exposure time intervals of 0–6 and 7–10 years, chances for preg-
nancy were higher in chlamydia-positive women compared with
chlamydia-negative women: aHRs, 1.54 (95% CI, 1.26–1.89)
and 1.42 (95% CI, 1.22–1.66), respectively. In the 2 last exposure
time categories of 11–13 and 13–23 years, no differences were
seen: aHRs, 0.93 (95% CI, 0.80–1.07) and 1.00 (95% CI,
0.90–1.10; Table 4).
Women With a Pregnancy Intention
In total, 2377 (41.7%)women had ever attempted to conceive.
After excluding records with missing values in time (n = 29) and
with an unclear number of pregnancies (n = 33), 2315 women
were included in the analyses. In total, the pregnancy proportion
was 87.4%. Overall 83.3% became pregnant within 12 months.
These were 85.0% (95% CI, 83.3%–86.7%) among chlamydia-
negative women and 77.9% (95% CI, 73.9%–81.5%) among
chlamydia-positive women. Of the remaining chlamydia-negative
women, 7.7% had a time to pregnancy >12 months and the re-
maining 7.3% had time <13 months but did not yet conceive.
For chlamydia positives, these were 11.6% and 10.7%, respec-
tively. Median (IQR) and mean (SD) time to pregnancy were 3
(IQR, 1–6) months and 5.6 (9.0) months for chlamydia negatives
and 3 (IQR, 1–7) months and 6.7 (11.0) months for chlamydia pos-
itives (P = 0.007; based on the Mann-WhitneyU test). The overall
pregnancy rate per person-year was 1.8 (95% CI, 1.7–1.9): 1.9 (95%
CI, 1.8–2.0) for chlamydia-negative women and 1.5 (95% CI,
1.3–1.6) for chlamydia-positive women. Figure 2B shows the
Kaplan-Meier curve. Time was censored at 36 months because
of sample size reduction. In Cox regression analyses, stratified for
age because of effect modification by age (i.e., age was divided into
tertiles), chances of pregnancy for chlamydia-positive women were
lower compared with chlamydia-negative women in the age catego-
ries 16–29 and 30–32 years (aHRs, 0.79 [95% CI, 0.67–0.94] and
0.74 [95% CI, 0.60–0.92], respectively; Table 5). In age category
TABLE 4. Association Between Chlamydia Status and Getting Pregnant by Exposure Time Intervals
Pregnancies Time Crude HR aHR
n* Person-Years† HR 95% CI P aHR 95% CI P
1. Years after sexual debut 0–6
Chlamydia negative 536 30,207 1 1
Chlamydia positive 148 2659 2.33 1.92–2.81 <0.01 1.54 1.26–1.89 <0.01
No infection 536 30,207 1 1
1 infection 123 2394 2.24 1.83–2.74 <0.01 1.50 1.21–1.86 <0.01
Multiple infections 25 265 3.07 2.16–4.37 <0.01 1.88 1.24–2.85 <0.01
2. Years after sexual debut 7–10
Chlamydia negative 637 17,103 1 1
Chlamydia positive 268 4047 1.37 1.18–1.58 <0.01 1.42 1.22–1.66 <0.01
No infection 637 17,103 1 1
1 infection 203 3295 1.33 1.14–1.56 <0.01 1.37 1.18–1.62 <0.01
Multiple infections 65 752 1.50 1.15–1.96 <0.01 1.67 1.25–2.24 <0.01
3. Years after sexual debut 11–13
Chlamydia negative 859 10,217 1 1
Chlamydia positive 229 3228 0.77 0.67–0.89 <0.01 0.93 0.80–1.07 0.32
No infection 859 10,217 1 1
1 infection 183 2536 0.79 0.68–0.92 <0.01 0.93 0.80–1.08 0.35
Multiple infections 46 692 0.68 0.51–0.90 0.01 0.93 0.69–1.25 0.63
4. Years after sexual debut 14–23
Chlamydia negative 1,690 12,447 1 1
Chlamydia positive 564 4637 0.86 0.78–0.95 >0.01 1.00 0.90–1.10 0.96
No infection 1,690 12,447 1 1
1 infection 443 3594 0.87 0.78–0.97 0.01 0.99 0.89–1.10 0.81
Multiple infections 121 1043 0.88 0.68–1.04 0.11 1.05 0.85–1.30 0.65
Chlamydia positive was defined as a positive NAAT test outcome in the CSI study (CSI-NAAT), and/or the presence of chlamydia IgG and/or a
self-reported chlamydia infection. For these analyses, multiple imputations were used to estimate time of first chlamydia infection in women without a known
first year of chlamydia infection. Models were adjusted for age, education level, migration background and number of lifetime partners.
*Complete cases.
†Person-years of complete cases.
aHR indicates adjusted hazard ratio; CI, confidence interval; HR, hazard ratio.
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33 to 39 years, no significant differencewas found (aHR, 1.07; 95%
CI, 0.89–1.28).
Sensitivity Analyses
Sensitivity analyses on pregnancies and time to pregnancy
using data restrictions as indicated in the methodology section
yielded comparable results (Supplementary Figs. 1 http://links.
lww.com/OLQ/A524 and 2 http://links.lww.com/OLQ/A525, and
Supplementary Tables 1 and 2 http://links.lww.com/OLQ/A526).
DISCUSSION
In this longitudinal cohort study with more than 10 years of
follow-up, we assessed pregnancies and time to pregnancy among
chlamydia-positive and chlamydia-negativewomen. Overall pregnancy
proportions (either planned or unplanned) in chlamydia-positive and
chlamydia-negative women were relatively similar. More chlamydia-
positive women were pregnant in the first 10 years after sexual de-
but, but this difference decreased thereafter. By contrast, among
women younger than 33 years with a pregnancy intention, preg-
nancy rates were lower in chlamydia-positive women compared
with chlamydia-negative women and time to pregnancy was longer.
No differences in pregnancy rates were seen after 33 years of age.
This unique cohort is a follow-up study from the population-
based CSI and included information on previous chlamydia in-
fections based on NAAT results, chlamydia IgG presence, and
self-reported positive test results, thereby reducing misclassifica-
tion. However, in common with other chlamydia studies, it is inev-
itable that there is misclassification in chlamydia status. Nucleic
acid amplification tests can only detect current infections, not past
infections, and these were performed only once per year in the
CSI.2 Serology can identify past infections, but sensitivity is not
optimal and serology was only done in the first NECCST ques-
tionnaire round, not in the second.14,19 Furthermore, participants
were classified as “chlamydia negative” (until first positive test result),
which could have been before first test outcome. Last, self-reported
infections may be subjected to recall bias. To understand the im-
pact of measurement bias, several sensitivity analyses were per-
formed that yielded similar results. The NECCST is a subset of
the population-based CSI study, and selection bias cannot be ruled
out. Participants were more often highly educated and from a
Western migration background than the general Dutch population.
However, our pregnancy results are quite comparable with the
general Dutch population. The average age of women when hav-
ing their first child in the Netherlands in 2013 (i.e., the median
year of first pregnancy in this cohort) was 29.4 years, which is
equal to the age of first pregnancy in this cohort. Furthermore,
in the Netherlands, approximately 83% of womenwhowish to be-
come pregnant conceive within 1 year, as similarly reported by
82% of women in this study.
In contrast to our hypothesis, overall pregnancy proportions
were rather comparable between chlamydia-positive and chlamydia-
negative women, both approximately 50% in the total cohort. We
expected lower pregnancy proportions because several studies, in-
cluding a previous study of this cohort, demonstrated a 1.3 to 4
times increased risk for TFI after chlamydia infection.8,20,21 Our re-
sults are, however, in agreement with population-based cohort stud-
ies fromDenmark andNorway, inwhich no differenceswere seen in
birth rates between chlamydia-seropositive women and chlamydia-
seronegative-tested women.12 In the population-based study from
Denmark, a slightly higher chance of births was seen for chlamydia-
positive women, either chlamydia seropositive or by a positive chla-
mydia DNA test.11 In a clinical study in Iran in which 250 infertile
couples were tested for chlamydia DNA and chlamydia serology,
no difference in pregnancy chances was found either.22 How can
this be explained? Although 1.3 to 4 times higher compared with
chlamydia-negativewomen, the risk for TFI after chlamydia infec-
tion is low (0.5%–1.0%).7 This effect might get lost in large cohorts
in which many other factors for getting pregnant played a role. We
did not have data about frequency of sexual contacts, which may
TABLE 5.Association Between Chlamydia Status andGetting Pregnant AmongWomenWith a Pregnancy Intention Stratified by Age at Time of
Attempting to Conceive
Planned Pregnancies Time Crude HR aHR
n* Person-Months† HR 95% CI P aHR 95% CI P
1. Age 16–29 y
Chlamydia negative 709 3871 1 1
Chlamydia positive 162 1374 0.78 0.66–0.92 <0.01 0.79 0.67–0.94 <0.01
No infection 709 3871 1 1
1 infection 132 1069 0.80 0.67–0.97 0.01 0.81 0.68–0.97 0.02
Multiple infections 30 305 0.71 0.49–1.03 0.07 0.71 0.49–1.03 0.07
2. Age 30–32 y
Chlamydia negative 425 2162 1 1
Chlamydia positive 98 692 0.72 0.59–0.89 <0.01 0.74 0.60–0.92 <0.01
No infection 425 2162 1 1
1 infection 79 571 0.72 0.58–0.90 <0.01 0.75 0.59–0.94 0.01
Multiple infections 19 121 0.71 0.45–1.13 0.15 0.72 0.45–1.14 0.16
3. Age 33–39 y
Chlamydia negative 485 3649 1 1
Chlamydia positive 131 842 1.07 0.89–1.28 0.48 1.07 0.89–1.28 0.49
No infection 485 3649 1 1
1 infection 115 690 1.11 0.92–1.34 0.29 1.10 0.90–1.33 0.35
Multiple infections 16 152 0.81 0.49–1.34 0.42 0.85 0.50–1.42 0.52
Chlamydia positive was defined as a positive NAAT test outcome in the CSI study (CSI-NAAT), and/or the presence of chlamydia IgG and/or a
self-reported chlamydia infection. For these analyses, multiple imputations were used to estimate time of first chlamydia infection in women without a known
first year of chlamydia infection. Analyses were stratified for age categories based on tertiles. All models were adjusted for age at pregnancy/trying to get
pregnant and migration background.
*Complete cases.
†Person-months of complete cases.
aHR indicates adjusted hazard ratio; CI, confidence interval; HR, hazard ratio.
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have had an impact.We found that unplanned pregnancies were sig-
nificantly more common (14% more) among chlamydia-positive
women compared with chlamydia-negative women. Because both
are linked to unprotected sexual contact, this is not unexpected.23
Despite not having information on sexual frequency, our results
imply that sexual activity among chlamydia-positivewomen could
have been higher, that is, significantly more lifetime partners, youn-
ger age at sexual debut, and more previous gonorrhea infections.
In the Netherlands, there is no antenatal chlamydia screening, but
it might be that part of unplanned pregnancies was terminated in
abortion clinics where women were offered a chlamydia test. More
chlamydia tests could have been done, which might have led to an
association between chlamydia positivity and pregnancy. However,
abortion rates in the Netherlands are low (8.8 per 1000 women in
2018), and only 8% of abortions were done among teenagers.24
Nevertheless, these factors in combination with less condom use
might have resulted in more pregnancies and explain why more
chlamydia-positive women were pregnant within the first 10 years
after sexual debut.
By contrast, among women with a pregnancy intention, preg-
nancy proportions and rates per year were lower among chlamydia-
positive women. These lower rates can only partly be explained
by the known TFI cases, which is only 1% in this cohort. Lower
pregnancy proportions were also seen in the study following up
infertile women with and without chlamydia antibodies where
fewer chlamydia-antibody–positivewomen became pregnant within
9months.25 In that study, other causes of infertility including visible
TFI were excluded. The possibility is that even without visible tubal
pathology, there might be intratubal microdamage due to a previous
chlamydia infection.25 On the other hand, we cannot completely rule
out selection bias for the effect. These lower pregnancy rates were
found among women with a pregnancy intention. In this analyses,
all women who only had an unplanned pregnancy were excluded.
In the questionnaire, women were asked if reported pregnancies
were “planned”without the definition of “planned” being explained
further. A planned pregnancy could have been interpreted differ-
ently betweenwomen andwrongly classified as “unplanned,”which
might explain our high rates of unplanned pregnancies. Although
excluding unplanned pregnancies led to more clear analyses, a
bias might be introduced because more chlamydia-positive women
had unplanned pregnancies, which could have either reduced or
underestimated the effect.
It is difficult to put our results in the context of chlamydia
control. In the Netherlands, extensive chlamydia control efforts are
being made. Youngsters up to the age of 25 years and high-risk
groups can be tested and treated for chlamydia free of charge.26
It is possible that because of the extensive testing and treating of
chlamydia infections, pregnancy rates are not lower in chlamydia-
positivewomen comparedwith chlamydia-negativewomen. How-
ever, we did see lower pregnancy rates among women with a
pregnancy intention. In sensitivity analyses in which we estimated
risks for women who were positive only by a chlamydia antibody
test and had not reported a chlamydia infection, and thus were pre-
sumably not treated for chlamydia, pregnancy rates did not differ
from chlamydia positives, of which the vast majority had been
treated. Although the group of chlamydia-positive women who
were presumably not treated for their infection was rather small,
it is possible that the effect of chlamydia control in preventing late
complications that might result in infertility is rather small.27
Using pregnancy rates and time to pregnancy in addition to
pelvic inflammatory disease, ectopic pregnancy, and TFI to study
reproductive health outcomes after chlamydia infections contributes
to the insight in chlamydia disease burden. Pregnancy characteris-
tics are easy to collect with high validity using questionnaires.28
Nevertheless, in using questionnaires to address events dating back
to years ago, recall bias cannot be ruled out. Given that in our study
the median number of years between first infection and first preg-
nancy was 5, we assume that not many first pregnancies were in-
correctly reported before first infection; however, this possibility
should be taken into account in interpreting the results.
To conclude, our results do not indicate that women with a
previous chlamydia infection have lower pregnancy chances com-
pared with women without a chlamydia infection. However, we
did find lower pregnancy rates and longer time to pregnancy
among women with a pregnancy intention, which could be due
to complications of the chlamydia infection caused by either vis-
ible or invisible tubal pathology. It is worthwhile to not only fo-
cus on chlamydia complications but also include pregnancy as
an outcome in surveillance and research.
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